ID   KPYM_HUMAN              Reviewed;         531 AA.
AC   P14618; A6NFK3; B2R5N8; B3KRY0; B4DFX8; B4DUU6; P14786; Q53GK4; Q96E76;
AC   Q9BWB5; Q9UCV6; Q9UPF2;
DT   01-APR-1990, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 4.
DT   18-JUN-2025, entry version 280.
DE   RecName: Full=Pyruvate kinase PKM;
DE            EC=2.7.1.40 {ECO:0000269|PubMed:15996096, ECO:0000269|PubMed:1854723, ECO:0000269|PubMed:20847263};
DE   AltName: Full=Cytosolic thyroid hormone-binding protein {ECO:0000303|PubMed:2813362};
DE            Short=CTHBP {ECO:0000303|PubMed:2813362};
DE   AltName: Full=Opa-interacting protein 3 {ECO:0000303|PubMed:9466265};
DE            Short=OIP-3 {ECO:0000303|PubMed:9466265};
DE   AltName: Full=Pyruvate kinase 2/3;
DE   AltName: Full=Pyruvate kinase muscle isozyme;
DE   AltName: Full=Threonine-protein kinase PKM2 {ECO:0000305};
DE            EC=2.7.11.1 {ECO:0000269|PubMed:22901803, ECO:0000269|PubMed:24120661};
DE   AltName: Full=Thyroid hormone-binding protein 1;
DE            Short=THBP1;
DE   AltName: Full=Tumor M2-PK;
DE   AltName: Full=Tyrosine-protein kinase PKM2 {ECO:0000305};
DE            EC=2.7.10.2 {ECO:0000269|PubMed:22306293, ECO:0000269|PubMed:24120661};
DE   AltName: Full=p58;
GN   Name=PKM; Synonyms=OIP3 {ECO:0000303|PubMed:9466265}, PK2, PK3, PKM2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM M2).
RC   TISSUE=Liver;
RX   PubMed=2854097; DOI=10.1016/0378-1119(88)90515-x;
RA   Tani K., Yoshida M.C., Satoh H., Mitamura K., Noguchi T., Tanaka T.,
RA   Fujii H., Miwa S.;
RT   "Human M2-type pyruvate kinase: cDNA cloning, chromosomal assignment and
RT   expression in hepatoma.";
RL   Gene 73:509-516(1988).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM M2), PROTEIN SEQUENCE OF 70-98,
RP   SUBUNIT, AND ACTIVITY REGULATION.
RX   PubMed=2813362; DOI=10.1073/pnas.86.20.7861;
RA   Kato H., Fukuda T., Parkison C., McPhie P., Cheng S.-Y.;
RT   "Cytosolic thyroid hormone-binding protein is a monomer of pyruvate
RT   kinase.";
RL   Proc. Natl. Acad. Sci. U.S.A. 86:7861-7865(1989).
RN   [3]
RP   ERRATUM OF PUBMED:2813362.
RA   Kato H., Fukuda T., Parkison C., McPhie P., Cheng S.-Y.;
RL   Proc. Natl. Acad. Sci. U.S.A. 87:1625-1625(1990).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND ALTERNATIVE SPLICING.
RX   PubMed=2040271; DOI=10.1111/j.1432-1033.1991.tb15991.x;
RA   Takenaka M., Noguchi T., Sadahiro S., Hirai H., Yamada K., Matsuda T.,
RA   Imai E., Tanaka T.;
RT   "Isolation and characterization of the human pyruvate kinase M gene.";
RL   Eur. J. Biochem. 198:101-106(1991).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS M1 AND 3).
RC   TISSUE=Astrocyte, and Fetal brain;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM M2).
RC   TISSUE=Kidney;
RA   Suzuki Y., Sugano S., Totoki Y., Toyoda A., Takeda T., Sakaki Y.,
RA   Tanaka A., Yokoyama S.;
RL   Submitted (APR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RG   NIEHS SNPs program;
RL   Submitted (JUL-2003) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16572171; DOI=10.1038/nature04601;
RA   Zody M.C., Garber M., Sharpe T., Young S.K., Rowen L., O'Neill K.,
RA   Whittaker C.A., Kamal M., Chang J.L., Cuomo C.A., Dewar K.,
RA   FitzGerald M.G., Kodira C.D., Madan A., Qin S., Yang X., Abbasi N.,
RA   Abouelleil A., Arachchi H.M., Baradarani L., Birditt B., Bloom S.,
RA   Bloom T., Borowsky M.L., Burke J., Butler J., Cook A., DeArellano K.,
RA   DeCaprio D., Dorris L. III, Dors M., Eichler E.E., Engels R., Fahey J.,
RA   Fleetwood P., Friedman C., Gearin G., Hall J.L., Hensley G., Johnson E.,
RA   Jones C., Kamat A., Kaur A., Locke D.P., Madan A., Munson G., Jaffe D.B.,
RA   Lui A., Macdonald P., Mauceli E., Naylor J.W., Nesbitt R., Nicol R.,
RA   O'Leary S.B., Ratcliffe A., Rounsley S., She X., Sneddon K.M.B.,
RA   Stewart S., Sougnez C., Stone S.M., Topham K., Vincent D., Wang S.,
RA   Zimmer A.R., Birren B.W., Hood L., Lander E.S., Nusbaum C.;
RT   "Analysis of the DNA sequence and duplication history of human chromosome
RT   15.";
RL   Nature 440:671-675(2006).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM M2), AND VARIANT VAL-204.
RC   TISSUE=Kidney, Lung carcinoma, Ovary, Retina, and Rhabdomyosarcoma;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [11]
RP   PROTEIN SEQUENCE OF 2-43; 57-73; 93-115; 126-135; 167-186; 231-246;
RP   271-311; 401-422; 448-455 AND 490-498, CLEAVAGE OF INITIATOR METHIONINE,
RP   ACETYLATION AT SER-2, AND IDENTIFICATION BY MASS SPECTROMETRY.
RC   TISSUE=B-cell lymphoma;
RA   Bienvenut W.V.;
RL   Submitted (JUL-2005) to UniProtKB.
RN   [12]
RP   PROTEIN SEQUENCE OF 2-18, FUNCTION, CATALYTIC ACTIVITY, ACTIVITY
RP   REGULATION, BIOPHYSICOCHEMICAL PROPERTIES, SUBUNIT, AND INTERACTION WITH
RP   THYROID HORMONE.
RX   PubMed=1854723; DOI=10.1021/bi00243a010;
RA   Ashizawa K., McPhie P., Lin K.-H., Cheng S.-Y.;
RT   "An in vitro novel mechanism of regulating the activity of pyruvate kinase
RT   M2 by thyroid hormone and fructose 1, 6-bisphosphate.";
RL   Biochemistry 30:7105-7111(1991).
RN   [13]
RP   PROTEIN SEQUENCE OF 2-32.
RC   TISSUE=Platelet;
RX   PubMed=12665801; DOI=10.1038/nbt810;
RA   Gevaert K., Goethals M., Martens L., Van Damme J., Staes A., Thomas G.R.,
RA   Vandekerckhove J.;
RT   "Exploring proteomes and analyzing protein processing by mass spectrometric
RT   identification of sorted N-terminal peptides.";
RL   Nat. Biotechnol. 21:566-569(2003).
RN   [14]
RP   PROTEIN SEQUENCE OF 74-89, AND IDENTIFICATION BY MASS SPECTROMETRY.
RC   TISSUE=Brain, and Cajal-Retzius cell;
RA   Lubec G., Vishwanath V.;
RL   Submitted (MAR-2007) to UniProtKB.
RN   [15]
RP   PROTEIN SEQUENCE OF 174-186; 295-305 AND 401-422 (ISOFORMS M2/3),
RP   INTERACTION WITH TRIM35 (ISOFORM M2), SUBCELLULAR LOCATION, AND MASS
RP   SPECTROMETRY.
RX   PubMed=25263439; DOI=10.1038/onc.2014.325;
RA   Chen Z., Wang Z., Guo W., Zhang Z., Zhao F., Zhao Y., Jia D., Ding J.,
RA   Wang H., Yao M., He X.;
RT   "TRIM35 Interacts with pyruvate kinase isoform M2 to suppress the Warburg
RT   effect and tumorigenicity in hepatocellular carcinoma.";
RL   Oncogene 34:3946-3956(2015).
RN   [16]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 368-531 (ISOFORM M2).
RX   PubMed=9466265; DOI=10.1046/j.1365-2958.1998.00670.x;
RA   Williams J.M., Chen G.-C., Zhu L., Rest R.F.;
RT   "Using the yeast two-hybrid system to identify human epithelial cell
RT   proteins that bind gonococcal Opa proteins: intracellular gonococci bind
RT   pyruvate kinase via their Opa proteins and require host pyruvate for
RT   growth.";
RL   Mol. Microbiol. 27:171-186(1998).
RN   [17]
RP   INTERACTION WITH HERC1.
RX   PubMed=12650930; DOI=10.1016/s0014-5793(03)00205-9;
RA   Garcia-Gonzalo F.R., Cruz C., Munoz P., Mazurek S., Eigenbrodt E.,
RA   Ventura F., Bartrons R., Rosa J.L.;
RT   "Interaction between HERC1 and M2-type pyruvate kinase.";
RL   FEBS Lett. 539:78-84(2003).
RN   [18]
RP   IDENTIFICATION BY MASS SPECTROMETRY.
RC   TISSUE=Lymphoblast;
RX   PubMed=14654843; DOI=10.1038/nature02166;
RA   Andersen J.S., Wilkinson C.J., Mayor T., Mortensen P., Nigg E.A., Mann M.;
RT   "Proteomic characterization of the human centrosome by protein correlation
RT   profiling.";
RL   Nature 426:570-574(2003).
RN   [19]
RP   ISGYLATION.
RX   PubMed=16139798; DOI=10.1016/j.bbrc.2005.08.132;
RA   Giannakopoulos N.V., Luo J.K., Papov V., Zou W., Lenschow D.J.,
RA   Jacobs B.S., Borden E.C., Li J., Virgin H.W., Zhang D.E.;
RT   "Proteomic identification of proteins conjugated to ISG15 in mouse and
RT   human cells.";
RL   Biochem. Biophys. Res. Commun. 336:496-506(2005).
RN   [20]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-105, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=15592455; DOI=10.1038/nbt1046;
RA   Rush J., Moritz A., Lee K.A., Guo A., Goss V.L., Spek E.J., Zhang H.,
RA   Zha X.-M., Polakiewicz R.D., Comb M.J.;
RT   "Immunoaffinity profiling of tyrosine phosphorylation in cancer cells.";
RL   Nat. Biotechnol. 23:94-101(2005).
RN   [21]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-37, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in signaling
RT   networks.";
RL   Cell 127:635-648(2006).
RN   [22]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-37, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=16964243; DOI=10.1038/nbt1240;
RA   Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.;
RT   "A probability-based approach for high-throughput protein phosphorylation
RT   analysis and site localization.";
RL   Nat. Biotechnol. 24:1285-1292(2006).
RN   [23]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=17308100; DOI=10.1158/0008-5472.can-06-2870;
RA   Stetak A., Veress R., Ovadi J., Csermely P., Keri G., Ullrich A.;
RT   "Nuclear translocation of the tumor marker pyruvate kinase M2 induces
RT   programmed cell death.";
RL   Cancer Res. 67:1602-1608(2007).
RN   [24]
RP   INTERACTION WITH PML, ACTIVITY REGULATION, SUBUNIT, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=18298799; DOI=10.1111/j.1365-2443.2008.01165.x;
RA   Shimada N., Shinagawa T., Ishii S.;
RT   "Modulation of M2-type pyruvate kinase activity by the cytoplasmic PML
RT   tumor suppressor protein.";
RL   Genes Cells 13:245-254(2008).
RN   [25]
RP   INTERACTION WITH POU5F1, IDENTIFICATION BY MASS SPECTROMETRY, FUNCTION,
RP   SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=18191611; DOI=10.1016/j.biocel.2007.11.009;
RA   Lee J., Kim H.K., Han Y.-M., Kim J.;
RT   "Pyruvate kinase isozyme type M2 (PKM2) interacts and cooperates with Oct-4
RT   in regulating transcription.";
RL   Int. J. Biochem. Cell Biol. 40:1043-1054(2008).
RN   [26]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-37, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Platelet;
RX   PubMed=18088087; DOI=10.1021/pr0704130;
RA   Zahedi R.P., Lewandrowski U., Wiesner J., Wortelkamp S., Moebius J.,
RA   Schuetz C., Walter U., Gambaryan S., Sickmann A.;
RT   "Phosphoproteome of resting human platelets.";
RL   J. Proteome Res. 7:526-534(2008).
RN   [27]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-37, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of the
RT   kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [28]
RP   FUNCTION (ISOFORMS M1 AND M2), TISSUE SPECIFICITY (ISOFORMS M1 AND M2), AND
RP   DEVELOPMENTAL STAGE (ISOFORMS M1 AND M2).
RX   PubMed=18337823; DOI=10.1038/nature06734;
RA   Christofk H.R., Vander Heiden M.G., Harris M.H., Ramanathan A.,
RA   Gerszten R.E., Wei R., Fleming M.D., Schreiber S.L., Cantley L.C.;
RT   "The M2 splice isoform of pyruvate kinase is important for cancer
RT   metabolism and tumour growth.";
RL   Nature 452:230-233(2008).
RN   [29]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-37, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [30]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [31]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-37; TYR-175 AND THR-195, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [32]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-62; LYS-89; LYS-166; LYS-266 AND
RP   LYS-433, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C.,
RA   Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [33]
RP   FUNCTION (ISOFORMS M1 AND M2), AND CATALYTIC ACTIVITY (ISOFORMS M1 AND M2).
RX   PubMed=20847263; DOI=10.1126/science.1188015;
RA   Vander Heiden M.G., Locasale J.W., Swanson K.D., Sharfi H., Heffron G.J.,
RA   Amador-Noguez D., Christofk H.R., Wagner G., Rabinowitz J.D., Asara J.M.,
RA   Cantley L.C.;
RT   "Evidence for an alternative glycolytic pathway in rapidly proliferating
RT   cells.";
RL   Science 329:1492-1499(2010).
RN   [34]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-37, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [35]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [36]
RP   INTERACTION WITH EGLN3 AND HIF1A, SUBCELLULAR LOCATION, INDUCTION,
RP   FUNCTION, IDENTIFICATION BY MASS SPECTROMETRY, HYDROXYLATION AT PRO-403 AND
RP   PRO-408, AND MUTAGENESIS OF PRO-403 AND PRO-408.
RX   PubMed=21620138; DOI=10.1016/j.cell.2011.03.054;
RA   Luo W., Hu H., Chang R., Zhong J., Knabel M., O'Meally R., Cole R.N.,
RA   Pandey A., Semenza G.L.;
RT   "Pyruvate kinase M2 is a PHD3-stimulated coactivator for hypoxia-inducible
RT   factor 1.";
RL   Cell 145:732-744(2011).
RN   [37]
RP   INTERACTION WITH EGLN3.
RX   PubMed=21483450; DOI=10.1038/cr.2011.66;
RA   Chen N., Rinner O., Czernik D., Nytko K.J., Zheng D., Stiehl D.P.,
RA   Zamboni N., Gstaiger M., Frei C.;
RT   "The oxygen sensor PHD3 limits glycolysis under hypoxia via direct binding
RT   to pyruvate kinase.";
RL   Cell Res. 21:983-986(2011).
RN   [38]
RP   ACETYLATION AT LYS-305.
RX   PubMed=21700219; DOI=10.1016/j.molcel.2011.04.025;
RA   Lv L., Li D., Zhao D., Lin R., Chu Y., Zhang H., Zha Z., Liu Y., Li Z.,
RA   Xu Y., Wang G., Huang Y., Xiong Y., Guan K.L., Lei Q.Y.;
RT   "Acetylation targets the M2 isoform of pyruvate kinase for degradation
RT   through chaperone-mediated autophagy and promotes tumor growth.";
RL   Mol. Cell 42:719-730(2011).
RN   [39]
RP   FUNCTION (ISOFORM M2), SUBCELLULAR LOCATION (ISOFORM M2), INTERACTION WITH
RP   CTNNB1 (ISOFORM M2), AND MUTAGENESIS OF LYS-367 AND LYS-433.
RX   PubMed=22056988; DOI=10.1038/nature10598;
RA   Yang W., Xia Y., Ji H., Zheng Y., Liang J., Huang W., Gao X., Aldape K.,
RA   Lu Z.;
RT   "Nuclear PKM2 regulates beta-catenin transactivation upon EGFR
RT   activation.";
RL   Nature 480:118-122(2011).
RN   [40]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-37, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [41]
RP   FUNCTION (ISOFORM M2), CATALYTIC ACTIVITY (ISOFORM M2), SUBCELLULAR
RP   LOCATION (ISOFORM M2), AND MUTAGENESIS OF LYS-367 AND LYS-433.
RX   PubMed=22901803; DOI=10.1016/j.cell.2012.07.018;
RA   Yang W., Xia Y., Hawke D., Li X., Liang J., Xing D., Aldape K., Hunter T.,
RA   Alfred Yung W.K., Lu Z.;
RT   "PKM2 phosphorylates histone H3 and promotes gene transcription and
RT   tumorigenesis.";
RL   Cell 150:685-696(2012).
RN   [42]
RP   FUNCTION (ISOFORM M2), CATALYTIC ACTIVITY (ISOFORM M2), SUBCELLULAR
RP   LOCATION (ISOFORM M2), SUBUNIT (ISOFORM M2), AND MUTAGENESIS OF ARG-399.
RX   PubMed=22306293; DOI=10.1016/j.molcel.2012.01.001;
RA   Gao X., Wang H., Yang J.J., Liu X., Liu Z.R.;
RT   "Pyruvate kinase M2 regulates gene transcription by acting as a protein
RT   kinase.";
RL   Mol. Cell 45:598-609(2012).
RN   [43]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-37; THR-41; TYR-105 AND
RP   SER-127, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [44]
RP   FUNCTION (ISOFORM M2), CATALYTIC ACTIVITY (ISOFORM M2), ACTIVITY REGULATION
RP   (ISOFORM M2), SUBCELLULAR LOCATION (ISOFORM M2), SUBUNIT (ISOFORM M2),
RP   ACETYLATION AT LYS-433 (ISOFORM M2), AND MUTAGENESIS OF LYS-433.
RX   PubMed=24120661; DOI=10.1016/j.molcel.2013.09.004;
RA   Lv L., Xu Y.P., Zhao D., Li F.L., Wang W., Sasaki N., Jiang Y., Zhou X.,
RA   Li T.T., Guan K.L., Lei Q.Y., Xiong Y.;
RT   "Mitogenic and oncogenic stimulation of K433 acetylation promotes PKM2
RT   protein kinase activity and nuclear localization.";
RL   Mol. Cell 52:340-352(2013).
RN   [45]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-37, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [46]
RP   METHYLATION [LARGE SCALE ANALYSIS] AT LYS-3, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Colon carcinoma;
RX   PubMed=24129315; DOI=10.1074/mcp.o113.027870;
RA   Guo A., Gu H., Zhou J., Mulhern D., Wang Y., Lee K.A., Yang V., Aguiar M.,
RA   Kornhauser J., Jia X., Ren J., Beausoleil S.A., Silva J.C., Vemulapalli V.,
RA   Bedford M.T., Comb M.J.;
RT   "Immunoaffinity enrichment and mass spectrometry analysis of protein
RT   methylation.";
RL   Mol. Cell. Proteomics 13:372-387(2014).
RN   [47]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-166, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25114211; DOI=10.1073/pnas.1413825111;
RA   Impens F., Radoshevich L., Cossart P., Ribet D.;
RT   "Mapping of SUMO sites and analysis of SUMOylation changes induced by
RT   external stimuli.";
RL   Proc. Natl. Acad. Sci. U.S.A. 111:12432-12437(2014).
RN   [48]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M., Ayoub D.,
RA   Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [49]
RP   INTERACTION WITH JMJD8.
RX   PubMed=27199445; DOI=10.1161/atvbaha.116.307695;
RA   Boeckel J.N., Derlet A., Glaser S.F., Luczak A., Lucas T., Heumueller A.W.,
RA   Krueger M., Zehendner C.M., Kaluza D., Doddaballapur A., Ohtani K.,
RA   Treguer K., Dimmeler S.;
RT   "JMJD8 Regulates Angiogenic Sprouting and Cellular Metabolism by
RT   Interacting With Pyruvate Kinase M2 in Endothelial Cells.";
RL   Arterioscler. Thromb. Vasc. Biol. 36:1425-1433(2016).
RN   [50]
RP   INTERACTION WITH TSC22D2, AND SUBCELLULAR LOCATION.
RX   PubMed=27573352; DOI=10.3892/ijo.2016.3599;
RA   Liang F., Li Q., Li X., Li Z., Gong Z., Deng H., Xiang B., Zhou M., Li X.,
RA   Li G., Zeng Z., Xiong W.;
RT   "TSC22D2 interacts with PKM2 and inhibits cell growth in colorectal
RT   cancer.";
RL   Int. J. Oncol. 49:1046-1056(2016).
RN   [51]
RP   FUNCTION (ISOFORM M2), SUBCELLULAR LOCATION (ISOFORM M2), ACETYLATION AT
RP   LYS-433 (ISOFORM M2), DEACETYLATION BY SIRT6 (ISOFORM M2), AND MUTAGENESIS
RP   OF LYS-433.
RX   PubMed=26787900; DOI=10.1073/pnas.1520045113;
RA   Bhardwaj A., Das S.;
RT   "SIRT6 deacetylates PKM2 to suppress its nuclear localization and oncogenic
RT   functions.";
RL   Proc. Natl. Acad. Sci. U.S.A. 113:E538-E547(2016).
RN   [52]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-115; LYS-266 AND LYS-270, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=28112733; DOI=10.1038/nsmb.3366;
RA   Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C.,
RA   Nielsen M.L.;
RT   "Site-specific mapping of the human SUMO proteome reveals co-modification
RT   with phosphorylation.";
RL   Nat. Struct. Mol. Biol. 24:325-336(2017).
RN   [53]
RP   S-NITROSYLATION AT CYS-423 AND CYS-424 (ISOFORM M2), AND MUTAGENESIS OF
RP   423-CYS-CYS-424.
RX   PubMed=30487609; DOI=10.1038/s41586-018-0749-z;
RA   Zhou H.L., Zhang R., Anand P., Stomberski C.T., Qian Z., Hausladen A.,
RA   Wang L., Rhee E.P., Parikh S.M., Karumanchi S.A., Stamler J.S.;
RT   "Metabolic reprogramming by the S-nitroso-CoA reductase system protects
RT   against kidney injury.";
RL   Nature 565:96-100(2019).
RN   [54]
RP   INTERACTION WITH TRAF4, AND SUBCELLULAR LOCATION.
RX   PubMed=32268273; DOI=10.1016/j.ebiom.2020.102722;
RA   Cen S., Li J., Cai Z., Pan Y., Sun Z., Li Z., Ye G., Zheng G., Li M.,
RA   Liu W., Yu W., Wang S., Xie Z., Wang P., Shen H.;
RT   "TRAF4 acts as a fate checkpoint to regulate the adipogenic differentiation
RT   of MSCs by activating PKM2.";
RL   EBioMedicine 54:102722-102722(2020).
RN   [55]
RP   X-RAY CRYSTALLOGRAPHY (2.82 ANGSTROMS) OF ISOFORM M2 IN COMPLEX WITH
RP   OXALATE AND FBP, CATALYTIC ACTIVITY, SUBUNIT, ENZYME MECHANISM, ACTIVITY
RP   REGULATION, FUNCTION, AND BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=15996096; DOI=10.1021/bi0474923;
RA   Dombrauckas J.D., Santarsiero B.D., Mesecar A.D.;
RT   "Structural basis for tumor pyruvate kinase M2 allosteric regulation and
RT   catalysis.";
RL   Biochemistry 44:9417-9429(2005).
RN   [56]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS).
RG   Structural genomics consortium (SGC);
RT   "Structure of human muscle pyruvate kinase (PKM2).";
RL   Submitted (MAY-2005) to the PDB data bank.
RN   [57]
RP   X-RAY CRYSTALLOGRAPHY (2.03 ANGSTROMS) OF 14-531 ALONE AND IN COMPLEX WITH
RP   FBP, FUNCTION, AND ACTIVITY REGULATION.
RX   PubMed=18337815; DOI=10.1038/nature06667;
RA   Christofk H.R., Vander Heiden M.G., Wu N., Asara J.M., Cantley L.C.;
RT   "Pyruvate kinase M2 is a phosphotyrosine-binding protein.";
RL   Nature 452:181-186(2008).
RN   [58]
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 2-531, ACTIVITY REGULATION BY
RP   SERINE, MAGNESIUM-BINDING SITES, SUBUNIT, AND MUTAGENESIS OF SER-437 AND
RP   HIS-464.
RX   PubMed=23064226; DOI=10.1038/nature11540;
RA   Chaneton B., Hillmann P., Zheng L., Martin A.C., Maddocks O.D.,
RA   Chokkathukalam A., Coyle J.E., Jankevics A., Holding F.P., Vousden K.H.,
RA   Frezza C., O'Reilly M., Gottlieb E.;
RT   "Serine is a natural ligand and allosteric activator of pyruvate kinase
RT   M2.";
RL   Nature 491:458-462(2012).
RN   [59]
RP   X-RAY CRYSTALLOGRAPHY (2.55 ANGSTROMS) IN COMPLEX WITH ATP;
RP   FRUCTOSE-1-6-DIPHOSPHATE; MAGNESIUM IONS AND POTASSIUM IONS.
RX   PubMed=23530218; DOI=10.1073/pnas.1217157110;
RA   Morgan H.P., O'Reilly F.J., Wear M.A., O'Neill J.R.,
RA   Fothergill-Gilmore L.A., Hupp T., Walkinshaw M.D.;
RT   "M2 pyruvate kinase provides a mechanism for nutrient sensing and
RT   regulation of cell proliferation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 110:5881-5886(2013).
CC   -!- FUNCTION: Catalyzes the final rate-limiting step of glycolysis by
CC       mediating the transfer of a phosphoryl group from phosphoenolpyruvate
CC       (PEP) to ADP, generating ATP (PubMed:15996096, PubMed:1854723,
CC       PubMed:20847263). The ratio between the highly active tetrameric form
CC       and nearly inactive dimeric form determines whether glucose carbons are
CC       channeled to biosynthetic processes or used for glycolytic ATP
CC       production (PubMed:15996096, PubMed:1854723, PubMed:20847263). The
CC       transition between the 2 forms contributes to the control of glycolysis
CC       and is important for tumor cell proliferation and survival
CC       (PubMed:15996096, PubMed:1854723, PubMed:20847263).
CC       {ECO:0000269|PubMed:15996096, ECO:0000269|PubMed:1854723,
CC       ECO:0000269|PubMed:20847263}.
CC   -!- FUNCTION: [Isoform M2]: Isoform specifically expressed during
CC       embryogenesis that has low pyruvate kinase activity by itself and
CC       requires allosteric activation by D-fructose 1,6-bisphosphate (FBP) for
CC       pyruvate kinase activity (PubMed:18337823, PubMed:20847263). In
CC       addition to its pyruvate kinase activity in the cytoplasm, also acts as
CC       a regulator of transcription in the nucleus by acting as a protein
CC       kinase (PubMed:18191611, PubMed:21620138, PubMed:22056988,
CC       PubMed:22306293, PubMed:22901803, PubMed:24120661). Translocates into
CC       the nucleus in response to various signals, such as EGF receptor
CC       activation, and homodimerizes, leading to its conversion into a protein
CC       threonine- and tyrosine-protein kinase (PubMed:22056988,
CC       PubMed:22306293, PubMed:22901803, PubMed:24120661, PubMed:26787900).
CC       Catalyzes phosphorylation of STAT3 at 'Tyr-705' and histone H3 at 'Thr-
CC       11' (H3T11ph), leading to activate transcription (PubMed:22306293,
CC       PubMed:22901803, PubMed:24120661). Its ability to activate
CC       transcription plays a role in cancer cells by promoting cell
CC       proliferation and promote tumorigenesis (PubMed:18337823,
CC       PubMed:22901803, PubMed:26787900). Promotes the expression of the
CC       immune checkpoint protein CD274 in BMAL1-deficient macrophages (By
CC       similarity). May also act as a translation regulator for a subset of
CC       mRNAs, independently of its pyruvate kinase activity: associates with
CC       subpools of endoplasmic reticulum-associated ribosomes, binds directly
CC       to the mRNAs translated at the endoplasmic reticulum and promotes
CC       translation of these endoplasmic reticulum-destined mRNAs (By
CC       similarity). Plays a role in caspase independent cell death of tumor
CC       cells (PubMed:17308100). {ECO:0000250|UniProtKB:P52480,
CC       ECO:0000269|PubMed:17308100, ECO:0000269|PubMed:18191611,
CC       ECO:0000269|PubMed:18337823, ECO:0000269|PubMed:20847263,
CC       ECO:0000269|PubMed:21620138, ECO:0000269|PubMed:22056988,
CC       ECO:0000269|PubMed:22306293, ECO:0000269|PubMed:22901803,
CC       ECO:0000269|PubMed:24120661, ECO:0000269|PubMed:26787900}.
CC   -!- FUNCTION: [Isoform M1]: Pyruvate kinase isoform expressed in adult
CC       tissues, which replaces isoform M2 after birth (PubMed:18337823). In
CC       contrast to isoform M2, has high pyruvate kinase activity by itself and
CC       does not require allosteric activation by D-fructose 1,6-bisphosphate
CC       (FBP) for activity (PubMed:20847263). {ECO:0000269|PubMed:18337823,
CC       ECO:0000269|PubMed:20847263}.
CC   -!- CATALYTIC ACTIVITY: [Isoform M2]:
CC       Reaction=pyruvate + ATP = phosphoenolpyruvate + ADP + H(+);
CC         Xref=Rhea:RHEA:18157, ChEBI:CHEBI:15361, ChEBI:CHEBI:15378,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:58702, ChEBI:CHEBI:456216;
CC         EC=2.7.1.40; Evidence={ECO:0000269|PubMed:15996096,
CC         ECO:0000269|PubMed:1854723, ECO:0000269|PubMed:20847263};
CC       PhysiologicalDirection=right-to-left; Xref=Rhea:RHEA:18159;
CC         Evidence={ECO:0000269|PubMed:15996096, ECO:0000269|PubMed:1854723,
CC         ECO:0000269|PubMed:20847263};
CC   -!- CATALYTIC ACTIVITY: [Isoform M2]:
CC       Reaction=L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] +
CC         ADP + H(+); Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA-
CC         COMP:20101, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858,
CC         ChEBI:CHEBI:61978, ChEBI:CHEBI:456216; EC=2.7.10.2;
CC         Evidence={ECO:0000269|PubMed:22306293, ECO:0000269|PubMed:24120661};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:10597;
CC         Evidence={ECO:0000269|PubMed:22306293, ECO:0000269|PubMed:24120661};
CC   -!- CATALYTIC ACTIVITY: [Isoform M2]:
CC       Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] +
CC         ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA-
CC         COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1;
CC         Evidence={ECO:0000269|PubMed:22901803, ECO:0000269|PubMed:24120661};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:46609;
CC         Evidence={ECO:0000269|PubMed:22901803, ECO:0000269|PubMed:24120661};
CC   -!- CATALYTIC ACTIVITY: [Isoform M1]:
CC       Reaction=pyruvate + ATP = phosphoenolpyruvate + ADP + H(+);
CC         Xref=Rhea:RHEA:18157, ChEBI:CHEBI:15361, ChEBI:CHEBI:15378,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:58702, ChEBI:CHEBI:456216;
CC         EC=2.7.1.40; Evidence={ECO:0000269|PubMed:20847263};
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC         Evidence={ECO:0000305|PubMed:23530218};
CC   -!- COFACTOR:
CC       Name=K(+); Xref=ChEBI:CHEBI:29103;
CC         Evidence={ECO:0000305|PubMed:23530218};
CC   -!- ACTIVITY REGULATION: [Isoform M2]: Isoform M2 is allosterically
CC       activated by D-fructose 1,6-bisphosphate (FBP) (PubMed:15996096,
CC       PubMed:18337815, PubMed:1854723, PubMed:2813362). Inhibited by oxalate
CC       and 3,3',5-triiodo-L-thyronine (T3) (PubMed:15996096). The activity of
CC       the tetrameric form is inhibited by PML (PubMed:18298799). Selective
CC       binding to tyrosine-phosphorylated peptides releases the allosteric
CC       activator FBP, leading to inhibition of PKM enzymatic activity, this
CC       diverts glucose metabolites from energy production to anabolic
CC       processes when cells are stimulated by certain growth factors
CC       (PubMed:18337815). Glycolytic flux are highly dependent on de novo
CC       biosynthesis of serine and glycine, and serine is a natural ligand and
CC       allosteric activator of isoform M2 (PubMed:23064226). Acetylation at
CC       Lys-433 promotes its translocation into the nucleus and
CC       homodimerization, promoting the protein kinase activity
CC       (PubMed:24120661). {ECO:0000269|PubMed:15996096,
CC       ECO:0000269|PubMed:18298799, ECO:0000269|PubMed:18337815,
CC       ECO:0000269|PubMed:1854723, ECO:0000269|PubMed:23064226,
CC       ECO:0000269|PubMed:24120661, ECO:0000269|PubMed:2813362}.
CC   -!- ACTIVITY REGULATION: [Isoform M1]: Has high pyruvate kinase activity by
CC       itself and does not require allosteric activation by D-fructose 1,6-
CC       bisphosphate (FBP) for activity. {ECO:0000269|PubMed:20847263}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=2.7 mM for phosphoenolpyruvate (at 32 degrees Celsius, pH 8.0)
CC         {ECO:0000269|PubMed:15996096, ECO:0000269|PubMed:1854723};
CC         KM=0.17 mM for phosphoenolpyruvate (in the presence of 2 mM
CC         D-fructose 1,6-bisphosphate (FBP), at 32 degrees Celsius, pH 8.0)
CC         {ECO:0000269|PubMed:15996096, ECO:0000269|PubMed:1854723};
CC         KM=0.34 mM for ADP (at 32 degrees Celsius, pH 8.0)
CC         {ECO:0000269|PubMed:15996096, ECO:0000269|PubMed:1854723};
CC         KM=0.24 mM for ADP (in the presence of 2 mM FBP, at 32 degrees
CC         Celsius, pH 8.0) {ECO:0000269|PubMed:15996096,
CC         ECO:0000269|PubMed:1854723};
CC         KM=0.13 mM for phosphoenolpyruvate (in the presence of 2 mM FBP, at
CC         25 degrees Celsius) {ECO:0000269|PubMed:15996096,
CC         ECO:0000269|PubMed:1854723};
CC         KM=0.63 mM for ADP (in the presence of 2 mM FBP, at 25 degrees
CC         Celsius) {ECO:0000269|PubMed:15996096, ECO:0000269|PubMed:1854723};
CC       pH dependence:
CC         Optimum pH for T3 binding is 6.0-6.5. Increase in pH causes T3
CC         binding to drop, does not bind T3 above pH 9.0 or below pH 5.0.
CC         {ECO:0000269|PubMed:15996096, ECO:0000269|PubMed:1854723};
CC   -!- PATHWAY: Carbohydrate degradation; glycolysis; pyruvate from D-
CC       glyceraldehyde 3-phosphate: step 5/5. {ECO:0000269|PubMed:15996096,
CC       ECO:0000269|PubMed:1854723}.
CC   -!- SUBUNIT: [Isoform M2]: Monomer and homotetramer; exists as a monomer in
CC       the absence of D-fructose 1,6-bisphosphate (FBP), and reversibly
CC       associates to form a homotetramer in the presence of FBP
CC       (PubMed:15996096, PubMed:18298799, PubMed:18337815, PubMed:1854723,
CC       PubMed:23064226, PubMed:2813362). The monomeric form binds 3,3',5-
CC       triiodo-L-thyronine (T3) (PubMed:15996096). Tetramer formation induces
CC       pyruvate kinase activity (PubMed:15996096, PubMed:18298799,
CC       PubMed:18337815, PubMed:1854723, PubMed:23064226, PubMed:2813362). The
CC       tetrameric form has high affinity for the substrate and is associated
CC       within the glycolytic enzyme complex (PubMed:15996096, PubMed:18298799,
CC       PubMed:18337815, PubMed:1854723, PubMed:23064226, PubMed:2813362). FBP
CC       stimulates the formation of tetramers from dimers (PubMed:15996096,
CC       PubMed:18298799, PubMed:18337815, PubMed:1854723, PubMed:23064226,
CC       PubMed:2813362). Homodimer; exists in a dimeric form in tumor cells and
CC       the dimeric form has less affinity for the phosphoenolpyruvate
CC       substrate (PubMed:22306293, PubMed:24120661). The homodimer converts
CC       into a protein kinase (PubMed:22306293, PubMed:24120661). Interacts
CC       with HERC1, POU5F1 and PML (PubMed:12650930, PubMed:18191611).
CC       Interacts with EGLN3; the interaction hydroxylates PKM under hypoxia
CC       and enhances binding to HIF1A (PubMed:21483450, PubMed:21620138).
CC       Interacts with HIF1A; the interaction is enhanced by binding of EGLN3,
CC       promoting enhanced transcription activity under hypoxia
CC       (PubMed:21620138). Interacts with TRIM35; this interaction prevents
CC       FGFR1-dependent tyrosine phosphorylation (PubMed:25263439). Interacts
CC       with JMJD8 (PubMed:27199445). Interacts with TRAF4 (PubMed:32268273).
CC       Interacts with (phosphorylated) CTNNB1; leading to activate
CC       transcription (PubMed:22056988). Interacts with TSC22D2; the
CC       interaction results in reduced nuclear levels of PKM isoform M2,
CC       leading to repression of cyclin CCND1 transcription and reduced cell
CC       growth (PubMed:27573352). {ECO:0000269|PubMed:12650930,
CC       ECO:0000269|PubMed:15996096, ECO:0000269|PubMed:18191611,
CC       ECO:0000269|PubMed:18298799, ECO:0000269|PubMed:18337815,
CC       ECO:0000269|PubMed:1854723, ECO:0000269|PubMed:21483450,
CC       ECO:0000269|PubMed:21620138, ECO:0000269|PubMed:22056988,
CC       ECO:0000269|PubMed:22306293, ECO:0000269|PubMed:23064226,
CC       ECO:0000269|PubMed:24120661, ECO:0000269|PubMed:25263439,
CC       ECO:0000269|PubMed:27199445, ECO:0000269|PubMed:27573352,
CC       ECO:0000269|PubMed:2813362, ECO:0000269|PubMed:32268273}.
CC   -!- SUBUNIT: (Microbial infection) Binding to certain oncoproteins such as
CC       HPV-16 E7 oncoprotein promotes homodimerization.
CC       {ECO:0000269|PubMed:24120661}.
CC   -!- INTERACTION:
CC       P14618; P49407: ARRB1; NbExp=3; IntAct=EBI-353408, EBI-743313;
CC       P14618; P32121: ARRB2; NbExp=4; IntAct=EBI-353408, EBI-714559;
CC       P14618; Q96IK1-2: BOD1; NbExp=3; IntAct=EBI-353408, EBI-18924329;
CC       P14618; P35222: CTNNB1; NbExp=4; IntAct=EBI-353408, EBI-491549;
CC       P14618; P53355: DAPK1; NbExp=3; IntAct=EBI-353408, EBI-358616;
CC       P14618; P22607: FGFR3; NbExp=3; IntAct=EBI-353408, EBI-348399;
CC       P14618; P42858: HTT; NbExp=9; IntAct=EBI-353408, EBI-466029;
CC       P14618; P04049: RAF1; NbExp=3; IntAct=EBI-353408, EBI-365996;
CC       P14618; Q8N488: RYBP; NbExp=3; IntAct=EBI-353408, EBI-752324;
CC       P14618; Q7Z699: SPRED1; NbExp=3; IntAct=EBI-353408, EBI-5235340;
CC       P14618; Q9BSI4: TINF2; NbExp=2; IntAct=EBI-353408, EBI-717399;
CC       P14618; Q9UMX0: UBQLN1; NbExp=3; IntAct=EBI-353408, EBI-741480;
CC       P14618; Q9Y649; NbExp=3; IntAct=EBI-353408, EBI-25900580;
CC       P14618; Q9WMX2; Xeno; NbExp=4; IntAct=EBI-353408, EBI-710918;
CC       P14618-1; P35222: CTNNB1; NbExp=3; IntAct=EBI-4304679, EBI-491549;
CC       P14618-1; P53355: DAPK1; NbExp=2; IntAct=EBI-4304679, EBI-358616;
CC       P14618-1; Q9H6Z9: EGLN3; NbExp=2; IntAct=EBI-4304679, EBI-1175354;
CC       P14618-1; P68431: H3C12; NbExp=3; IntAct=EBI-4304679, EBI-79722;
CC       P14618-1; Q16665: HIF1A; NbExp=7; IntAct=EBI-4304679, EBI-447269;
CC       P14618-1; P27361: MAPK3; NbExp=3; IntAct=EBI-4304679, EBI-73995;
CC   -!- SUBCELLULAR LOCATION: [Isoform M2]: Cytoplasm
CC       {ECO:0000269|PubMed:25263439, ECO:0000269|PubMed:26787900,
CC       ECO:0000269|PubMed:27573352, ECO:0000269|PubMed:32268273}. Nucleus
CC       {ECO:0000269|PubMed:17308100, ECO:0000269|PubMed:18191611,
CC       ECO:0000269|PubMed:22056988, ECO:0000269|PubMed:22901803,
CC       ECO:0000269|PubMed:24120661, ECO:0000269|PubMed:26787900,
CC       ECO:0000269|PubMed:27573352, ECO:0000269|PubMed:32268273}.
CC       Note=Translocates to the nucleus in response to various signals, such
CC       as EGF receptor activation or apoptotic stimuli (PubMed:17308100,
CC       PubMed:22056988, PubMed:24120661). Nuclear translocation is promoted by
CC       acetylation by EP300 (PubMed:24120661). Deacetylation by SIRT6 promotes
CC       its nuclear export in a process dependent of XPO4, thereby suppressing
CC       its ability to activate transcription and promote tumorigenesis
CC       (PubMed:26787900). {ECO:0000269|PubMed:17308100,
CC       ECO:0000269|PubMed:22056988, ECO:0000269|PubMed:24120661,
CC       ECO:0000269|PubMed:26787900}.
CC   -!- SUBCELLULAR LOCATION: [Isoform M1]: Cytoplasm {ECO:0000305}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=M2 {ECO:0000303|PubMed:2854097}; Synonyms=M2-PK, PKM2;
CC         IsoId=P14618-1; Sequence=Displayed;
CC       Name=M1 {ECO:0000303|PubMed:2854097}; Synonyms=M1-PK, PKM1;
CC         IsoId=P14618-2, P14786-1; Sequence=VSP_011101;
CC       Name=3;
CC         IsoId=P14618-3; Sequence=VSP_043370;
CC   -!- TISSUE SPECIFICITY: [Isoform M2]: Specifically expressed in
CC       proliferating cells, such as embryonic stem cells, embryonic carcinoma
CC       cells, as well as cancer cells. {ECO:0000269|PubMed:18191611,
CC       ECO:0000269|PubMed:18337823}.
CC   -!- TISSUE SPECIFICITY: [Isoform M1]: Expressed in adult tissues
CC       (PubMed:18337823). Not expressed in tumor cells (PubMed:18337823).
CC       {ECO:0000269|PubMed:18337823}.
CC   -!- DEVELOPMENTAL STAGE: [Isoform M2]: Specifically expressed during
CC       embryonic development. {ECO:0000269|PubMed:18337823}.
CC   -!- DEVELOPMENTAL STAGE: [Isoform M1]: Specifically expressed in adult
CC       tissues. {ECO:0000269|PubMed:18337823}.
CC   -!- PTM: ISGylated. {ECO:0000269|PubMed:16139798}.
CC   -!- PTM: Under hypoxia, hydroxylated by EGLN3.
CC       {ECO:0000269|PubMed:21620138}.
CC   -!- PTM: Acetylation at Lys-305 is stimulated by high glucose
CC       concentration, it decreases enzyme activity and promotes its lysosomal-
CC       dependent degradation via chaperone-mediated autophagy.
CC       {ECO:0000269|PubMed:21700219, ECO:0000269|Ref.11}.
CC   -!- PTM: [Isoform M2]: Acetylated at Lys-433 by EP300, leading to impair
CC       phosphoenolpyruvate substrate-binding and promote its homodimerization
CC       and subsequent translocation to the nucleus (PubMed:24120661).
CC       Deacetylation at Lys-433 by SIRT6 promotes its nuclear export into the
CC       cytoplasm, leading to suppress its nuclear localization and oncogenic
CC       function (PubMed:26787900). {ECO:0000269|PubMed:24120661,
CC       ECO:0000269|PubMed:26787900}.
CC   -!- PTM: [Isoform M2]: S-nitrosylation at Cys-423 and Cys-424 inhibits
CC       homotetramerization and pyruvate kinase activity (PubMed:30487609). S-
CC       nitrosylation is indirectly inhibited by AKR1A1 which degrades S-
CC       nitroso-CoA, a cofactor required to S-nitrosylate proteins
CC       (PubMed:30487609). {ECO:0000269|PubMed:30487609}.
CC   -!- PTM: FGFR1-dependent tyrosine phosphorylation is reduced by interaction
CC       with TRIM35. {ECO:0000269|PubMed:25263439}.
CC   -!- MISCELLANEOUS: There are 4 isozymes of pyruvate kinase in mammals (L,
CC       R, M1, M2) encoded by 2 different genes: PKLR and PKM. The L and R
CC       isozymes are generated from the PKLR by differential splicing of RNA;
CC       the M1 and M2 forms are produced from the PKM gene by differential
CC       splicing. L type is major isozyme in the liver, R is found in red
CC       cells, M1 is the main form in muscle, heart and brain, and M2 is found
CC       in early fetal tissues as well as in most cancer cells.
CC   -!- SIMILARITY: Belongs to the pyruvate kinase family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAG57589.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Pyruvate kinase entry;
CC       URL="https://en.wikipedia.org/wiki/Pyruvate_kinase";
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="https://atlasgeneticsoncology.org/gene/41728/PKM2";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M23725; AAA36449.1; -; mRNA.
DR   EMBL; M26252; AAA36672.1; -; mRNA.
DR   EMBL; X56494; CAA39849.1; -; Genomic_DNA.
DR   EMBL; AK092369; BAG52542.1; -; mRNA.
DR   EMBL; AK222927; BAD96647.1; -; mRNA.
DR   EMBL; AK294315; BAG57589.1; ALT_INIT; mRNA.
DR   EMBL; AK300800; BAG62458.1; -; mRNA.
DR   EMBL; AK312253; BAG35185.1; -; mRNA.
DR   EMBL; AY352517; AAQ15274.1; -; Genomic_DNA.
DR   EMBL; AC020779; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471082; EAW77884.1; -; Genomic_DNA.
DR   EMBL; CH471082; EAW77888.1; -; Genomic_DNA.
DR   EMBL; BC000481; AAH00481.3; -; mRNA.
DR   EMBL; BC007640; AAH07640.1; -; mRNA.
DR   EMBL; BC007952; AAH07952.3; -; mRNA.
DR   EMBL; BC012811; AAH12811.3; -; mRNA.
DR   EMBL; BC035198; AAH35198.1; -; mRNA.
DR   EMBL; AF025439; AAC39559.1; -; mRNA.
DR   CCDS; CCDS32284.1; -. [P14618-1]
DR   CCDS; CCDS32285.1; -. [P14618-2]
DR   PIR; S30038; S30038.
DR   PIR; S64635; S64635.
DR   RefSeq; NP_001193725.1; NM_001206796.2.
DR   RefSeq; NP_001193726.1; NM_001206797.2.
DR   RefSeq; NP_001193727.1; NM_001206798.3. [P14618-3]
DR   RefSeq; NP_001193728.1; NM_001206799.1.
DR   RefSeq; NP_001303247.1; NM_001316318.1.
DR   RefSeq; NP_002645.3; NM_002654.5. [P14618-1]
DR   RefSeq; NP_872270.1; NM_182470.4. [P14618-2]
DR   RefSeq; NP_872271.1; NM_182471.4. [P14618-2]
DR   RefSeq; XP_005254502.1; XM_005254445.6. [P14618-1]
DR   RefSeq; XP_016877802.1; XM_017022313.1.
DR   RefSeq; XP_047288622.1; XM_047432666.1. [P14618-1]
DR   PDB; 1T5A; X-ray; 2.80 A; A/B/C/D=1-531.
DR   PDB; 1ZJH; X-ray; 2.20 A; A=3-531.
DR   PDB; 3BJF; X-ray; 2.03 A; A/B/C/D=14-531.
DR   PDB; 3BJT; X-ray; 2.50 A; A/B/C/D=2-531.
DR   PDB; 3G2G; X-ray; 2.00 A; A/B/C/D=1-531.
DR   PDB; 3GQY; X-ray; 1.85 A; A/B/C/D=1-531.
DR   PDB; 3GR4; X-ray; 1.60 A; A/B/C/D=1-531.
DR   PDB; 3H6O; X-ray; 2.00 A; A/B/C/D=1-531.
DR   PDB; 3ME3; X-ray; 1.95 A; A/B/C/D=1-531.
DR   PDB; 3SRD; X-ray; 2.90 A; A/B/C/D=1-531.
DR   PDB; 3SRF; X-ray; 2.84 A; A/B/C/D/E/F/G/H=1-531.
DR   PDB; 3SRH; X-ray; 2.60 A; A/B/C/D=1-531.
DR   PDB; 3U2Z; X-ray; 2.10 A; A/B/C/D=1-531.
DR   PDB; 4B2D; X-ray; 2.30 A; A/B/C/D=2-531.
DR   PDB; 4FXF; X-ray; 2.55 A; A/B/C/D=1-531.
DR   PDB; 4FXJ; X-ray; 2.90 A; A/B/C/D=1-531.
DR   PDB; 4G1N; X-ray; 2.30 A; A/B/C/D=14-531.
DR   PDB; 4JPG; X-ray; 2.33 A; A/B/C/D=1-531.
DR   PDB; 4QG6; X-ray; 3.21 A; A/B/C/D=1-531.
DR   PDB; 4QG8; X-ray; 2.30 A; A/B/C/D=1-531.
DR   PDB; 4QG9; X-ray; 2.38 A; A/B/C/D=1-531.
DR   PDB; 4QGC; X-ray; 2.30 A; A/B/C/D=1-531.
DR   PDB; 4RPP; X-ray; 2.58 A; A/B/C/D=1-531.
DR   PDB; 4WJ8; X-ray; 2.87 A; A/B/C/D=1-531.
DR   PDB; 4YJ5; X-ray; 2.41 A; A/B/C/D=14-531.
DR   PDB; 5X0I; X-ray; 2.64 A; A/B/C/D=1-531.
DR   PDB; 5X1V; X-ray; 2.10 A; A/B/C/D=1-531.
DR   PDB; 5X1W; X-ray; 3.00 A; A/B/C/D=1-531.
DR   PDB; 6B6U; X-ray; 1.35 A; A/B=7-531.
DR   PDB; 6GG3; X-ray; 3.72 A; A/B/C/D/E/F/G/H/I/J/K/L=1-531.
DR   PDB; 6GG4; X-ray; 2.46 A; A/B/C/D=1-531.
DR   PDB; 6GG5; X-ray; 3.20 A; A/B/C/D=1-531.
DR   PDB; 6GG6; X-ray; 2.96 A; A/B/C/D/E/F/G/H=1-531.
DR   PDB; 6JFB; X-ray; 2.12 A; A/B/C/D=1-531.
DR   PDB; 6NU1; X-ray; 2.25 A; A/B/C/D=1-531.
DR   PDB; 6NU5; X-ray; 1.60 A; A/B=1-531.
DR   PDB; 6NUB; X-ray; 1.70 A; A/B=1-531.
DR   PDB; 6TTF; EM; 3.20 A; A/B/C/D=2-531.
DR   PDB; 6TTH; EM; 2.60 A; A/B/C/D=2-531.
DR   PDB; 6TTI; EM; 2.50 A; A/B/C/D=2-531.
DR   PDB; 6TTQ; EM; 2.70 A; A/B/C/D=2-531.
DR   PDB; 6V74; X-ray; 2.32 A; A/B/C/D=1-531.
DR   PDB; 6V75; X-ray; 2.85 A; A/B/C/D=1-531.
DR   PDB; 6V76; X-ray; 2.75 A; A/B/C/D=1-531.
DR   PDB; 6WP3; X-ray; 1.84 A; A/B=1-531.
DR   PDB; 6WP4; X-ray; 1.90 A; A/B/C/D=1-531.
DR   PDB; 6WP5; X-ray; 2.17 A; A/B/C/D=1-531.
DR   PDB; 6WP6; X-ray; 2.45 A; A/C=1-531.
DR   PDB; 7L21; X-ray; 2.29 A; A/B/C/D=1-531.
DR   PDB; 8G2E; X-ray; 1.84 A; A=1-531.
DR   PDB; 8HGF; X-ray; 3.10 A; A/B/C/D=1-531.
DR   PDB; 8HMQ; X-ray; 2.50 A; A/B/C/D=1-531.
DR   PDB; 8HMR; X-ray; 2.60 A; A/B/C/D=1-531.
DR   PDB; 8HMS; X-ray; 2.10 A; A/B/C/D=1-531.
DR   PDB; 8HMU; X-ray; 2.50 A; A/B/C/D=1-531.
DR   PDB; 8X4R; X-ray; 2.18 A; A/B/C/D=1-531.
DR   PDBsum; 1T5A; -.
DR   PDBsum; 1ZJH; -.
DR   PDBsum; 3BJF; -.
DR   PDBsum; 3BJT; -.
DR   PDBsum; 3G2G; -.
DR   PDBsum; 3GQY; -.
DR   PDBsum; 3GR4; -.
DR   PDBsum; 3H6O; -.
DR   PDBsum; 3ME3; -.
DR   PDBsum; 3SRD; -.
DR   PDBsum; 3SRF; -.
DR   PDBsum; 3SRH; -.
DR   PDBsum; 3U2Z; -.
DR   PDBsum; 4B2D; -.
DR   PDBsum; 4FXF; -.
DR   PDBsum; 4FXJ; -.
DR   PDBsum; 4G1N; -.
DR   PDBsum; 4JPG; -.
DR   PDBsum; 4QG6; -.
DR   PDBsum; 4QG8; -.
DR   PDBsum; 4QG9; -.
DR   PDBsum; 4QGC; -.
DR   PDBsum; 4RPP; -.
DR   PDBsum; 4WJ8; -.
DR   PDBsum; 4YJ5; -.
DR   PDBsum; 5X0I; -.
DR   PDBsum; 5X1V; -.
DR   PDBsum; 5X1W; -.
DR   PDBsum; 6B6U; -.
DR   PDBsum; 6GG3; -.
DR   PDBsum; 6GG4; -.
DR   PDBsum; 6GG5; -.
DR   PDBsum; 6GG6; -.
DR   PDBsum; 6JFB; -.
DR   PDBsum; 6NU1; -.
DR   PDBsum; 6NU5; -.
DR   PDBsum; 6NUB; -.
DR   PDBsum; 6TTF; -.
DR   PDBsum; 6TTH; -.
DR   PDBsum; 6TTI; -.
DR   PDBsum; 6TTQ; -.
DR   PDBsum; 6V74; -.
DR   PDBsum; 6V75; -.
DR   PDBsum; 6V76; -.
DR   PDBsum; 6WP3; -.
DR   PDBsum; 6WP4; -.
DR   PDBsum; 6WP5; -.
DR   PDBsum; 6WP6; -.
DR   PDBsum; 7L21; -.
DR   PDBsum; 8G2E; -.
DR   PDBsum; 8HGF; -.
DR   PDBsum; 8HMQ; -.
DR   PDBsum; 8HMR; -.
DR   PDBsum; 8HMS; -.
DR   PDBsum; 8HMU; -.
DR   PDBsum; 8X4R; -.
DR   AlphaFoldDB; P14618; -.
DR   EMDB; EMD-10575; -.
DR   EMDB; EMD-10576; -.
DR   EMDB; EMD-10577; -.
DR   EMDB; EMD-10584; -.
DR   SMR; P14618; -.
DR   BioGRID; 111332; 511.
DR   ComplexPortal; CPX-3057; PKM2 pyruvate kinase complex (dimer). [P14618-1]
DR   ComplexPortal; CPX-3058; PKM2 pyruvate kinase complex (tetramer). [P14618-1]
DR   ComplexPortal; CPX-3093; PKM1 pyruvate kinase complex. [P14618-2]
DR   CORUM; P14618; -.
DR   DIP; DIP-31273N; -.
DR   FunCoup; P14618; 1373.
DR   IntAct; P14618; 315.
DR   MINT; P14618; -.
DR   STRING; 9606.ENSP00000320171; -.
DR   BindingDB; P14618; -.
DR   ChEMBL; CHEMBL1075189; -.
DR   DrugBank; DB07697; 1-(2,3-dihydro-1,4-benzodioxin-6-ylsulfonyl)-4-[(4-methoxyphenyl)sulfonyl]piperazine.
DR   DrugBank; DB07692; 1-[(2,6-difluorophenyl)sulfonyl]-4-(2,3-dihydro-1,4-benzodioxin-6-ylsulfonyl)piperazine.
DR   DrugBank; DB02726; 2-Phosphoglycolic Acid.
DR   DrugBank; DB07628; 6-(2-fluorobenzyl)-2,4-dimethyl-4,6-dihydro-5H-thieno[2',3':4,5]pyrrolo[2,3-d]pyridazin-5-one.
DR   DrugBank; DB00787; Acyclovir.
DR   DrugBank; DB11638; Artenimol.
DR   DrugBank; DB09130; Copper.
DR   DrugBank; DB08951; Indoprofen.
DR   DrugBank; DB01733; L-Phospholactate.
DR   DrugBank; DB11263; Polydatin.
DR   DrugBank; DB00119; Pyruvic acid.
DR   DrugBank; DB12088; TT-232.
DR   DrugCentral; P14618; -.
DR   GuidetoPHARMACOLOGY; 3006; -.
DR   MoonDB; P14618; Curated.
DR   MoonProt; P14618; -.
DR   GlyCosmos; P14618; 3 sites, 1 glycan.
DR   GlyGen; P14618; 6 sites, 1 O-linked glycan (5 sites).
DR   iPTMnet; P14618; -.
DR   MetOSite; P14618; -.
DR   PhosphoSitePlus; P14618; -.
DR   SwissPalm; P14618; -.
DR   BioMuta; PKM; -.
DR   DMDM; 20178296; -.
DR   OGP; P14618; -.
DR   REPRODUCTION-2DPAGE; IPI00220644; -.
DR   REPRODUCTION-2DPAGE; IPI00479186; -.
DR   CPTAC; CPTAC-2745; -.
DR   jPOST; P14618; -.
DR   MassIVE; P14618; -.
DR   PaxDb; 9606-ENSP00000320171; -.
DR   PeptideAtlas; P14618; -.
DR   PRIDE; P14618; -.
DR   ProteomicsDB; 53065; -. [P14618-3]
DR   Pumba; P14618; -.
DR   TopDownProteomics; P14618-1; -. [P14618-1]
DR   TopDownProteomics; P14618-2; -. [P14618-2]
DR   Antibodypedia; 14162; 1224 antibodies from 45 providers.
DR   CPTC; P14618; 1 antibody.
DR   DNASU; 5315; -.
DR   Ensembl; ENST00000319622.10; ENSP00000320171.6; ENSG00000067225.21. [P14618-2]
DR   Ensembl; ENST00000335181.10; ENSP00000334983.5; ENSG00000067225.21. [P14618-1]
DR   Ensembl; ENST00000568459.5; ENSP00000456970.1; ENSG00000067225.21. [P14618-2]
DR   GeneID; 5315; -.
DR   KEGG; hsa:5315; -.
DR   MANE-Select; ENST00000335181.10; ENSP00000334983.5; NM_002654.6; NP_002645.3.
DR   UCSC; uc002atw.2; human. [P14618-1]
DR   AGR; HGNC:9021; -.
DR   CTD; 5315; -.
DR   DisGeNET; 5315; -.
DR   GeneCards; PKM; -.
DR   HGNC; HGNC:9021; PKM.
DR   HPA; ENSG00000067225; Tissue enhanced (skeletal muscle, tongue).
DR   MalaCards; PKM; -.
DR   MIM; 179050; gene.
DR   OpenTargets; ENSG00000067225; -.
DR   VEuPathDB; HostDB:ENSG00000067225; -.
DR   eggNOG; KOG2323; Eukaryota.
DR   GeneTree; ENSGT00390000008859; -.
DR   HOGENOM; CLU_015439_0_1_1; -.
DR   InParanoid; P14618; -.
DR   OMA; RVHHIGE; -.
DR   OrthoDB; 108365at2759; -.
DR   PAN-GO; P14618; 4 GO annotations based on evolutionary models.
DR   PhylomeDB; P14618; -.
DR   BioCyc; MetaCyc:HS00906-MONOMER; -.
DR   BRENDA; 2.7.1.40; 2681.
DR   PathwayCommons; P14618; -.
DR   Reactome; R-HSA-6798695; Neutrophil degranulation.
DR   Reactome; R-HSA-70171; Glycolysis.
DR   Reactome; R-HSA-70268; Pyruvate metabolism.
DR   Reactome; R-HSA-9861718; Regulation of pyruvate metabolism. [P14618-1]
DR   SABIO-RK; P14618; -.
DR   SignaLink; P14618; -.
DR   SIGNOR; P14618; -.
DR   UniPathway; UPA00109; UER00188.
DR   BioGRID-ORCS; 5315; 628 hits in 1182 CRISPR screens.
DR   CD-CODE; 91857CE7; Nucleolus.
DR   CD-CODE; FB4E32DD; Presynaptic clusters and postsynaptic densities.
DR   ChiTaRS; PKM; human.
DR   EvolutionaryTrace; P14618; -.
DR   GeneWiki; PKM2; -.
DR   GenomeRNAi; 5315; -.
DR   Pharos; P14618; Tchem.
DR   PRO; PR:P14618; -.
DR   Proteomes; UP000005640; Chromosome 15.
DR   RNAct; P14618; protein.
DR   Bgee; ENSG00000067225; Expressed in right hemisphere of cerebellum and 208 other cell types or tissues.
DR   ExpressionAtlas; P14618; baseline and differential.
DR   GO; GO:0005929; C:cilium; IEA:Ensembl.
DR   GO; GO:0062023; C:collagen-containing extracellular matrix; HDA:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:1903561; C:extracellular vesicle; HDA:UniProtKB.
DR   GO; GO:1904813; C:ficolin-1-rich granule lumen; TAS:Reactome.
DR   GO; GO:0043231; C:intracellular membrane-bounded organelle; IDA:HPA.
DR   GO; GO:0005739; C:mitochondrion; HDA:UniProtKB.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0005791; C:rough endoplasmic reticulum; ISS:UniProtKB.
DR   GO; GO:0034774; C:secretory granule lumen; TAS:Reactome.
DR   GO; GO:0031982; C:vesicle; HDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0045296; F:cadherin binding; HDA:BHF-UCL.
DR   GO; GO:0035402; F:histone H3T11 kinase activity; IDA:UniProtKB.
DR   GO; GO:0000287; F:magnesium ion binding; IEA:InterPro.
DR   GO; GO:0023026; F:MHC class II protein complex binding; HDA:UniProtKB.
DR   GO; GO:0003729; F:mRNA binding; ISS:UniProtKB.
DR   GO; GO:0030955; F:potassium ion binding; IEA:InterPro.
DR   GO; GO:0042803; F:protein homodimerization activity; IDA:UniProtKB.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; IDA:UniProtKB.
DR   GO; GO:0004743; F:pyruvate kinase activity; IDA:UniProtKB.
DR   GO; GO:0003723; F:RNA binding; HDA:UniProtKB.
DR   GO; GO:0003713; F:transcription coactivator activity; IDA:UniProtKB.
DR   GO; GO:0061621; P:canonical glycolysis; IEA:Ensembl.
DR   GO; GO:0032869; P:cellular response to insulin stimulus; IBA:GO_Central.
DR   GO; GO:0006096; P:glycolytic process; IDA:UniProt.
DR   GO; GO:2000767; P:positive regulation of cytoplasmic translation; ISS:UniProtKB.
DR   GO; GO:1903672; P:positive regulation of sprouting angiogenesis; IMP:UniProtKB.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:UniProtKB.
DR   GO; GO:0012501; P:programmed cell death; IDA:UniProtKB.
DR   CDD; cd00288; Pyruvate_Kinase; 1.
DR   FunFam; 3.20.20.60:FF:000025; Pyruvate kinase; 1.
DR   FunFam; 3.40.1380.20:FF:000001; Pyruvate kinase; 1.
DR   FunFam; 3.40.1380.20:FF:000002; Pyruvate kinase; 1.
DR   FunFam; 2.40.33.10:FF:000023; Pyruvate kinase PKM; 1.
DR   Gene3D; 3.20.20.60; Phosphoenolpyruvate-binding domains; 1.
DR   Gene3D; 2.40.33.10; PK beta-barrel domain-like; 1.
DR   Gene3D; 3.40.1380.20; Pyruvate kinase, C-terminal domain; 2.
DR   InterPro; IPR001697; Pyr_Knase.
DR   InterPro; IPR015813; Pyrv/PenolPyrv_kinase-like_dom.
DR   InterPro; IPR040442; Pyrv_kinase-like_dom_sf.
DR   InterPro; IPR011037; Pyrv_Knase-like_insert_dom_sf.
DR   InterPro; IPR018209; Pyrv_Knase_AS.
DR   InterPro; IPR015793; Pyrv_Knase_brl.
DR   InterPro; IPR015795; Pyrv_Knase_C.
DR   InterPro; IPR036918; Pyrv_Knase_C_sf.
DR   InterPro; IPR015806; Pyrv_Knase_insert_dom_sf.
DR   NCBIfam; NF004491; PRK05826.1; 1.
DR   NCBIfam; NF004978; PRK06354.1; 1.
DR   NCBIfam; TIGR01064; pyruv_kin; 1.
DR   PANTHER; PTHR11817; PYRUVATE KINASE; 1.
DR   Pfam; PF00224; PK; 1.
DR   Pfam; PF02887; PK_C; 1.
DR   PRINTS; PR01050; PYRUVTKNASE.
DR   SUPFAM; SSF51621; Phosphoenolpyruvate/pyruvate domain; 1.
DR   SUPFAM; SSF50800; PK beta-barrel domain-like; 1.
DR   SUPFAM; SSF52935; PK C-terminal domain-like; 1.
DR   PROSITE; PS00110; PYRUVATE_KINASE; 1.
DR   neXtProt; NX_P14618; -.
DR   PharmGKB; PA33353; -.
DR   TreeFam; TF300390; -.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Allosteric enzyme; Alternative splicing;
KW   ATP-binding; Cytoplasm; Direct protein sequencing; Glycolysis;
KW   Hydroxylation; Isopeptide bond; Kinase; Magnesium; Metal-binding;
KW   Methylation; Nucleotide-binding; Nucleus; Phosphoprotein; Potassium;
KW   Proteomics identification; Pyruvate; Reference proteome; S-nitrosylation;
KW   Transferase; Translation regulation; Ubl conjugation.
FT   INIT_MET        1
FT                   /note="Removed"
FT                   /evidence="ECO:0000269|PubMed:12665801,
FT                   ECO:0000269|PubMed:1854723, ECO:0000269|Ref.11,
FT                   ECO:0007744|PubMed:19413330, ECO:0007744|PubMed:25944712"
FT   CHAIN           2..531
FT                   /note="Pyruvate kinase PKM"
FT                   /id="PRO_0000112088"
FT   REGION          307..531
FT                   /note="Interaction with POU5F1"
FT                   /evidence="ECO:0000269|PubMed:18191611"
FT   REGION          389..433
FT                   /note="Intersubunit contact"
FT   BINDING         70
FT                   /ligand="L-serine"
FT                   /ligand_id="ChEBI:CHEBI:33384"
FT                   /evidence="ECO:0000269|PubMed:23064226"
FT   BINDING         73
FT                   /ligand="substrate"
FT                   /evidence="ECO:0000250|UniProtKB:P30613"
FT   BINDING         75..78
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000269|PubMed:23530218,
FT                   ECO:0007744|PDB:4FXF"
FT   BINDING         75
FT                   /ligand="K(+)"
FT                   /ligand_id="ChEBI:CHEBI:29103"
FT                   /evidence="ECO:0000269|PubMed:23530218,
FT                   ECO:0007744|PDB:4FXF"
FT   BINDING         77
FT                   /ligand="K(+)"
FT                   /ligand_id="ChEBI:CHEBI:29103"
FT                   /evidence="ECO:0000269|PubMed:23530218,
FT                   ECO:0007744|PDB:4FXF"
FT   BINDING         106
FT                   /ligand="L-serine"
FT                   /ligand_id="ChEBI:CHEBI:33384"
FT                   /evidence="ECO:0000269|PubMed:23064226"
FT   BINDING         113
FT                   /ligand="K(+)"
FT                   /ligand_id="ChEBI:CHEBI:29103"
FT                   /evidence="ECO:0000269|PubMed:23530218,
FT                   ECO:0007744|PDB:4FXF"
FT   BINDING         114
FT                   /ligand="K(+)"
FT                   /ligand_id="ChEBI:CHEBI:29103"
FT                   /evidence="ECO:0000269|PubMed:23530218,
FT                   ECO:0007744|PDB:4FXF"
FT   BINDING         120
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000269|PubMed:23530218,
FT                   ECO:0007744|PDB:4FXF"
FT   BINDING         207
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000269|PubMed:23530218,
FT                   ECO:0007744|PDB:4FXF"
FT   BINDING         270
FT                   /ligand="substrate"
FT                   /evidence="ECO:0000250|UniProtKB:P30613"
FT   BINDING         272
FT                   /ligand="Mg(2+)"
FT                   /ligand_id="ChEBI:CHEBI:18420"
FT                   /evidence="ECO:0000269|PubMed:23530218,
FT                   ECO:0007744|PDB:4FXF"
FT   BINDING         295
FT                   /ligand="substrate"
FT                   /evidence="ECO:0000250|UniProtKB:P30613"
FT   BINDING         296
FT                   /ligand="Mg(2+)"
FT                   /ligand_id="ChEBI:CHEBI:18420"
FT                   /evidence="ECO:0000269|PubMed:23530218,
FT                   ECO:0007744|PDB:4FXF"
FT   BINDING         296
FT                   /ligand="substrate"
FT                   /evidence="ECO:0000250|UniProtKB:P30613"
FT   BINDING         328
FT                   /ligand="substrate"
FT                   /evidence="ECO:0000250|UniProtKB:P30613"
FT   BINDING         432..437
FT                   /ligand="beta-D-fructose 1,6-bisphosphate"
FT                   /ligand_id="ChEBI:CHEBI:32966"
FT                   /ligand_note="allosteric activator"
FT                   /evidence="ECO:0000269|PubMed:15996096,
FT                   ECO:0000269|PubMed:23530218, ECO:0007744|PDB:1T5A,
FT                   ECO:0007744|PDB:4FXF"
FT   BINDING         464
FT                   /ligand="L-serine"
FT                   /ligand_id="ChEBI:CHEBI:33384"
FT                   /evidence="ECO:0000269|PubMed:23064226"
FT   BINDING         482
FT                   /ligand="beta-D-fructose 1,6-bisphosphate"
FT                   /ligand_id="ChEBI:CHEBI:32966"
FT                   /ligand_note="allosteric activator"
FT                   /evidence="ECO:0000269|PubMed:15996096,
FT                   ECO:0000269|PubMed:23530218, ECO:0007744|PDB:1T5A,
FT                   ECO:0007744|PDB:4FXF"
FT   BINDING         489
FT                   /ligand="beta-D-fructose 1,6-bisphosphate"
FT                   /ligand_id="ChEBI:CHEBI:32966"
FT                   /ligand_note="allosteric activator"
FT                   /evidence="ECO:0000269|PubMed:15996096,
FT                   ECO:0000269|PubMed:23530218, ECO:0007744|PDB:1T5A,
FT                   ECO:0007744|PDB:4FXF"
FT   BINDING         516..521
FT                   /ligand="beta-D-fructose 1,6-bisphosphate"
FT                   /ligand_id="ChEBI:CHEBI:32966"
FT                   /ligand_note="allosteric activator"
FT                   /evidence="ECO:0000269|PubMed:15996096,
FT                   ECO:0000269|PubMed:23530218, ECO:0007744|PDB:1T5A,
FT                   ECO:0007744|PDB:4FXF"
FT   SITE            270
FT                   /note="Transition state stabilizer"
FT                   /evidence="ECO:0000250|UniProtKB:P00549"
FT   SITE            433
FT                   /note="Crucial for phosphotyrosine binding"
FT                   /evidence="ECO:0000269|PubMed:27199445"
FT   MOD_RES         2
FT                   /note="N-acetylserine"
FT                   /evidence="ECO:0000269|Ref.11, ECO:0007744|PubMed:19413330,
FT                   ECO:0007744|PubMed:25944712"
FT   MOD_RES         3
FT                   /note="N6,N6,N6-trimethyllysine"
FT                   /evidence="ECO:0007744|PubMed:24129315"
FT   MOD_RES         37
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:16964243,
FT                   ECO:0007744|PubMed:17081983, ECO:0007744|PubMed:18088087,
FT                   ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:18691976,
FT                   ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163,
FT                   ECO:0007744|PubMed:24275569"
FT   MOD_RES         41
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         62
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         66
FT                   /note="N6-succinyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P52480"
FT   MOD_RES         89
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         97
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P11980"
FT   MOD_RES         100
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P11980"
FT   MOD_RES         105
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0007744|PubMed:15592455,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         127
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         148
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000250|UniProtKB:P52480"
FT   MOD_RES         166
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         166
FT                   /note="N6-succinyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:P52480"
FT   MOD_RES         175
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0007744|PubMed:19690332"
FT   MOD_RES         195
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:19690332"
FT   MOD_RES         266
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         270
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:P52480"
FT   MOD_RES         305
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000269|PubMed:21700219"
FT   MOD_RES         322
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:P52480"
FT   MOD_RES         322
FT                   /note="N6-succinyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:P52480"
FT   MOD_RES         403
FT                   /note="4-hydroxyproline"
FT                   /evidence="ECO:0000269|PubMed:21620138"
FT   MOD_RES         408
FT                   /note="4-hydroxyproline"
FT                   /evidence="ECO:0000269|PubMed:21620138"
FT   MOD_RES         423
FT                   /note="S-nitrosocysteine"
FT                   /evidence="ECO:0000269|PubMed:30487609"
FT   MOD_RES         424
FT                   /note="S-nitrosocysteine"
FT                   /evidence="ECO:0000269|PubMed:30487609"
FT   MOD_RES         433
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000269|PubMed:24120661,
FT                   ECO:0000269|PubMed:26787900, ECO:0007744|PubMed:19608861"
FT   MOD_RES         475
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P52480"
FT   MOD_RES         498
FT                   /note="N6-succinyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P52480"
FT   CROSSLNK        115
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        166
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO1); alternate"
FT                   /evidence="ECO:0007744|PubMed:25114211"
FT   CROSSLNK        266
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2); alternate"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        270
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2); alternate"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   VAR_SEQ         1..82
FT                   /note="MSKPHSEAGTAFIQTQQLHAAMADTFLEHMCRLDIDSPPITARNTGIICTIG
FT                   PASRSVETLKEMIKSGMNVARLNFSHGTHE -> MSPEAQPQRTKGPQQPCRSPIVKPG
FT                   LPSFRPSSCTQPWLTHSWSTCAAWTLIHHPSQPGTLASSVPL (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_043370"
FT   VAR_SEQ         389..433
FT                   /note="IYHLQLFEELRRLAPITSDPTEATAVGAVEASFKCCSGAIIVLTK -> MFH
FT                   RKLFEELVRASSHSTDLMEAMAMGSVEASYKCLAAALIVLTE (in isoform M1)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_011101"
FT   VARIANT         204
FT                   /note="G -> V (in dbSNP:rs17853396)"
FT                   /evidence="ECO:0000269|PubMed:15489334"
FT                   /id="VAR_033067"
FT   MUTAGEN         367
FT                   /note="K->M: Abolishes both pyruvate kinase and protein
FT                   kinase activities."
FT                   /evidence="ECO:0000269|PubMed:22056988,
FT                   ECO:0000269|PubMed:22901803"
FT   MUTAGEN         399
FT                   /note="R->E: Impaired homotetramerization, leading to
FT                   homodimerization and subsequent activation of the protein
FT                   kinase activity."
FT                   /evidence="ECO:0000269|PubMed:22306293"
FT   MUTAGEN         403
FT                   /note="P->A: Significant reduction in hydroxylation and in
FT                   PKM-mediated transcriptional activity of HIF1A; when
FT                   associated with A-408."
FT                   /evidence="ECO:0000269|PubMed:21620138"
FT   MUTAGEN         408
FT                   /note="P->A: Significant reduction in hydroxylation and in
FT                   PKM-mediated transcriptional activity of HIF1A; when
FT                   associated with A-403."
FT                   /evidence="ECO:0000269|PubMed:21620138"
FT   MUTAGEN         423..424
FT                   /note="CC->AA: Abolished S-nitrosylation, leading to
FT                   increased pyruvate kinase activity."
FT                   /evidence="ECO:0000269|PubMed:30487609"
FT   MUTAGEN         433
FT                   /note="K->E: Abolished interaction with phosphorylated
FT                   CTNNB1. Impaired phosphorylation of histone H3."
FT                   /evidence="ECO:0000269|PubMed:22056988,
FT                   ECO:0000269|PubMed:22901803"
FT   MUTAGEN         433
FT                   /note="K->Q: Mimics acetylation, promoting homodimerization
FT                   and activation of the protein kinase activity."
FT                   /evidence="ECO:0000269|PubMed:24120661,
FT                   ECO:0000269|PubMed:26787900"
FT   MUTAGEN         433
FT                   /note="K->R: Abolished acetylation by EP300. Abolished
FT                   deacetylation by SIRT6."
FT                   /evidence="ECO:0000269|PubMed:24120661,
FT                   ECO:0000269|PubMed:26787900"
FT   MUTAGEN         437
FT                   /note="S->Y: Unable to bind FBP but still activated by
FT                   serine."
FT                   /evidence="ECO:0000269|PubMed:23064226"
FT   MUTAGEN         464
FT                   /note="H->A: Abolishes serine binding and allosteric
FT                   activation."
FT                   /evidence="ECO:0000269|PubMed:23064226"
FT   CONFLICT        7
FT                   /note="E -> Q (in Ref. 10; AAH12811)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        54
FT                   /note="A -> T (in Ref. 5; BAG52542)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        103
FT                   /note="I -> Y (in Ref. 2; AAA36672)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        132
FT                   /note="V -> L (in Ref. 2; AAA36672)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        187
FT                   /note="Q -> R (in Ref. 6; BAD96647)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        252
FT                   /note="H -> R (in Ref. 6; BAD96647)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        339
FT                   /note="R -> P (in Ref. 4; CAA39849)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        349
FT                   /note="A -> V (in Ref. 5; BAG52542)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        379
FT                   /note="H -> N (in Ref. 1; AAA36449)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        507
FT                   /note="D -> H (in Ref. 10; AAH12811)"
FT                   /evidence="ECO:0000305"
FT   HELIX           9..11
FT                   /evidence="ECO:0007829|PDB:6B6U"
FT   TURN            15..17
FT                   /evidence="ECO:0007829|PDB:6V74"
FT   HELIX           18..21
FT                   /evidence="ECO:0007829|PDB:6B6U"
FT   STRAND          23..25
FT                   /evidence="ECO:0007829|PDB:6WP4"
FT   HELIX           26..31
FT                   /evidence="ECO:0007829|PDB:6B6U"
FT   STRAND          35..37
FT                   /evidence="ECO:0007829|PDB:4QGC"
FT   STRAND          45..50
FT                   /evidence="ECO:0007829|PDB:6B6U"
FT   TURN            53..55
FT                   /evidence="ECO:0007829|PDB:6B6U"
FT   HELIX           58..67
FT                   /evidence="ECO:0007829|PDB:6B6U"
FT   STRAND          71..75
FT                   /evidence="ECO:0007829|PDB:6B6U"
FT   TURN            76..78
FT                   /evidence="ECO:0007829|PDB:6GG6"
FT   HELIX           81..96
FT                   /evidence="ECO:0007829|PDB:6B6U"
FT   TURN            97..100
FT                   /evidence="ECO:0007829|PDB:6B6U"
FT   TURN            102..104
FT                   /evidence="ECO:0007829|PDB:6B6U"
FT   STRAND          109..113
FT                   /evidence="ECO:0007829|PDB:6B6U"
FT   STRAND          119..121
FT                   /evidence="ECO:0007829|PDB:6B6U"
FT   TURN            125..127
FT                   /evidence="ECO:0007829|PDB:6B6U"
FT   STRAND          128..130
FT                   /evidence="ECO:0007829|PDB:4WJ8"
FT   STRAND          132..134
FT                   /evidence="ECO:0007829|PDB:6B6U"
FT   STRAND          139..143
FT                   /evidence="ECO:0007829|PDB:6B6U"
FT   HELIX           146..148
FT                   /evidence="ECO:0007829|PDB:6B6U"
FT   STRAND          154..160
FT                   /evidence="ECO:0007829|PDB:6B6U"
FT   HELIX           164..167
FT                   /evidence="ECO:0007829|PDB:6B6U"
FT   STRAND          173..176
FT                   /evidence="ECO:0007829|PDB:6B6U"
FT   TURN            177..180
FT                   /evidence="ECO:0007829|PDB:6B6U"
FT   STRAND          181..188
FT                   /evidence="ECO:0007829|PDB:6B6U"
FT   STRAND          190..199
FT                   /evidence="ECO:0007829|PDB:6B6U"
FT   STRAND          201..203
FT                   /evidence="ECO:0007829|PDB:6B6U"
FT   STRAND          204..206
FT                   /evidence="ECO:0007829|PDB:4B2D"
FT   STRAND          208..210
FT                   /evidence="ECO:0007829|PDB:6B6U"
FT   STRAND          212..214
FT                   /evidence="ECO:0007829|PDB:5X1V"
FT   HELIX           223..234
FT                   /evidence="ECO:0007829|PDB:6B6U"
FT   STRAND          238..242
FT                   /evidence="ECO:0007829|PDB:6B6U"
FT   HELIX           248..257
FT                   /evidence="ECO:0007829|PDB:6B6U"
FT   TURN            258..264
FT                   /evidence="ECO:0007829|PDB:6B6U"
FT   STRAND          265..271
FT                   /evidence="ECO:0007829|PDB:6B6U"
FT   HELIX           274..278
FT                   /evidence="ECO:0007829|PDB:6B6U"
FT   HELIX           280..286
FT                   /evidence="ECO:0007829|PDB:6B6U"
FT   STRAND          287..293
FT                   /evidence="ECO:0007829|PDB:6B6U"
FT   HELIX           294..300
FT                   /evidence="ECO:0007829|PDB:6B6U"
FT   HELIX           303..305
FT                   /evidence="ECO:0007829|PDB:6B6U"
FT   HELIX           306..320
FT                   /evidence="ECO:0007829|PDB:6B6U"
FT   STRAND          324..329
FT                   /evidence="ECO:0007829|PDB:6B6U"
FT   HELIX           332..335
FT                   /evidence="ECO:0007829|PDB:6B6U"
FT   STRAND          337..339
FT                   /evidence="ECO:0007829|PDB:6NU5"
FT   HELIX           342..354
FT                   /evidence="ECO:0007829|PDB:6B6U"
FT   STRAND          357..362
FT                   /evidence="ECO:0007829|PDB:6B6U"
FT   HELIX           363..366
FT                   /evidence="ECO:0007829|PDB:6B6U"
FT   STRAND          367..369
FT                   /evidence="ECO:0007829|PDB:1ZJH"
FT   HELIX           371..388
FT                   /evidence="ECO:0007829|PDB:6B6U"
FT   HELIX           391..400
FT                   /evidence="ECO:0007829|PDB:6B6U"
FT   TURN            402..404
FT                   /evidence="ECO:0007829|PDB:3SRF"
FT   HELIX           408..423
FT                   /evidence="ECO:0007829|PDB:6B6U"
FT   STRAND          428..431
FT                   /evidence="ECO:0007829|PDB:6B6U"
FT   STRAND          433..435
FT                   /evidence="ECO:0007829|PDB:6B6U"
FT   HELIX           436..442
FT                   /evidence="ECO:0007829|PDB:6B6U"
FT   STRAND          450..455
FT                   /evidence="ECO:0007829|PDB:6B6U"
FT   HELIX           457..462
FT                   /evidence="ECO:0007829|PDB:6B6U"
FT   HELIX           463..465
FT                   /evidence="ECO:0007829|PDB:6B6U"
FT   STRAND          469..473
FT                   /evidence="ECO:0007829|PDB:6B6U"
FT   HELIX           482..499
FT                   /evidence="ECO:0007829|PDB:6B6U"
FT   STRAND          508..512
FT                   /evidence="ECO:0007829|PDB:6B6U"
FT   TURN            517..519
FT                   /evidence="ECO:0007829|PDB:3G2G"
FT   STRAND          525..529
FT                   /evidence="ECO:0007829|PDB:6B6U"
SQ   SEQUENCE   531 AA;  57937 MW;  AA94D7818ED6BBAD CRC64;
     MSKPHSEAGT AFIQTQQLHA AMADTFLEHM CRLDIDSPPI TARNTGIICT IGPASRSVET
     LKEMIKSGMN VARLNFSHGT HEYHAETIKN VRTATESFAS DPILYRPVAV ALDTKGPEIR
     TGLIKGSGTA EVELKKGATL KITLDNAYME KCDENILWLD YKNICKVVEV GSKIYVDDGL
     ISLQVKQKGA DFLVTEVENG GSLGSKKGVN LPGAAVDLPA VSEKDIQDLK FGVEQDVDMV
     FASFIRKASD VHEVRKVLGE KGKNIKIISK IENHEGVRRF DEILEASDGI MVARGDLGIE
     IPAEKVFLAQ KMMIGRCNRA GKPVICATQM LESMIKKPRP TRAEGSDVAN AVLDGADCIM
     LSGETAKGDY PLEAVRMQHL IAREAEAAIY HLQLFEELRR LAPITSDPTE ATAVGAVEAS
     FKCCSGAIIV LTKSGRSAHQ VARYRPRAPI IAVTRNPQTA RQAHLYRGIF PVLCKDPVQE
     AWAEDVDLRV NFAMNVGKAR GFFKKGDVVI VLTGWRPGSG FTNTMRVVPV P
//
